In:
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, Bentham Science Publishers Ltd., Vol. 21, No. 2 ( 2021-06), p. 115-120
Abstract:
Coronavirus disease-2019 (COVID-19) is a global pandemic health problem
that causes a wide spectrum of clinical manifestations and considerable mortality rates. Unfortunately, recovered patients who survive COVID-19 may continue to report a wide variety of clinical
manifestations of multisystem affection such as pulmonary embolism, deep vein thrombosis, acute myocardial infarction, depression, anxiety, myalgia, dyspnea, and fatigue. Objective: We aimed to summarize the current literature regarding the prevalence of post-COVID- 19 manifestations. Methods: We conducted a systematic review of post-COVID-19 manifestations by searching
MEDLINE via PubMed, Scopus, Web of Science (WOS), EBSCO, Wily, and World health organization (WHO) databases. Screening, study selection, data extraction, data synthesis, and quality
assessment were made by two independent reviewers. Results: Of 1,371 references, 817 references remained after removing duplicates. Reviews, case
reports, commentaries, and any article containing non-original information were excluded. According to the eligibility criteria for this systematic review, 12 studies were included for qualitative
synthesis. The overall prevalence of post-COVID-19 manifestations ranged from 35% to 90.5%. Fatigue, dyspnea, neuropsychological disorders, and pain were the most frequent post-COVID-19
symptoms. Conclusion: This systematic review showed that 35% to 90.5% of recovered patients who survive
COVID-19 continue to have a wide variety of clinical manifestations, including fatigue, dyspnea, neuropsychological disorders, and pain as the most frequent post-COVID-19 symptoms.
Type of Medium:
Online Resource
ISSN:
1871-5230
DOI:
10.2174/1871523021666220328115818
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2021
SSG:
15,3
Permalink
